| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C27H36F3N7O5S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
ABD957 is a potent, selective covalent inhibitor of the ABHD17 family of depalmitoylases, with an IC50 of 0.21 μM against ABHD17B. It can block N-Ras signaling and the growth of NRAS-mutant AML cells[1]. It is supplied as a white to off-white solid (C27H36F3N7O5S, MW 627.68) at 98.14% purity.
Physical & Chemical Properties
| CAS Number | 3007772-60-0 |
|---|---|
| Molecular Formula | C27H36F3N7O5S |
| Molecular Weight | 627.68 g/mol |
| Purity | 98.14% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | C[C@H]1CN(CCN1C(N2C=CC(S(=O)(N(C)C)=O)=N2)=O)CC3=C(C=C(C=C3)C(F)(F)F)N4C5CCC4CN(C5)CC(O)=O |
| Signaling Pathway | Metabolic Enzyme/Protease |
| Solubility | In Vitro: DMSO: 100 mg/mL (159.32 mM; Requires sonication and warming and heat to 160°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: 0.21 μM (ABHD17B)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (159.32 mM) | requires sonication and warming and heat to 160°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | 5 mg/mL (7.97 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 5 mg/mL. For 1 mL of working solution: add 100 μL DMSO stock (50.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 5 mg/mL (7.97 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 5 mg/mL. For 1 mL of working solution: add 100 μL DMSO stock (50.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
In AML cells, pretreatment with ABD957 (500 nM; 1 h) reduces N-Ras depalmitoylation[1]. ABD957 (0.11 nM-10 μM; 72 h) blocks signaling and proliferation in NRAS-mutant leukemia cells[1].
Cell Proliferation Assay[1]
| Cell Line | OCI-AML3, THP1, HL60, NB-4 and NOMO1 cells |
|---|---|
| Concentration | 0.1, 1, 10, 100, 1000, 10000 nM |
| Incubation Time | 72 hours |
| Result | Reduced the growth of NRAS-mutant AML cell lines (OCI-AML3, THP1 and HL60), but not KRAS mutant cell lines (NB-4 and NOMO1). |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Palmitoylation modification of SPI1 promotes nasopharyngeal carcinoma radioresistance through inhibiting c-CBL-mediated ubiquitination and degradation. Drug Resist Updat 2026 May:86:101374. PMID: 41691772
ASCT2 palmitoylation regulated by JNK1-ZDHHC14 axis orchestrates glutamine metabolism and NSCLC progression. Cell Discov 2026 Feb 24;12(1):13. PMID: 41730846
Palmitoyltransferase ZDHHC3 Aggravates Nonalcoholic Steatohepatitis by Targeting S-Palmitoylated IRHOM2. Adv Sci (Weinh) 2023 Oct;10(28):e2302130. PMID: 37544908
